“Is curing patients a sustainable business model?” Goldman Sachs analysts ask
by Beth Mole from Ars Technica - All content on (#3MKPB)
Enlarge / The Goldman Sachs bank logo is seen reflected on the screen of a mobile phone in this photo illustration on November 15, 2017. (credit: Jaap Arriens/NurPhoto via Getty Images)
One-shot cures for diseases are not great for business-more specifically, they're bad for longterm profits-Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks' report, titled "The Genome Revolution," asks clients the touchy question: "Is curing patients a sustainable business model?" The answer may be "no," according to follow-up information provided.
Analyst Salveen Richter and colleagues laid it out:
Read 5 remaining paragraphs | Comments